These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 23290775)

  • 1. Interdiction of sphingolipid metabolism to improve standard cancer therapies.
    Beckham TH; Cheng JC; Marrison ST; Norris JS; Liu X
    Adv Cancer Res; 2013; 117():1-36. PubMed ID: 23290775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.
    Voelkel-Johnson C; Norris JS; White-Gilbertson S
    Adv Cancer Res; 2018; 140():265-293. PubMed ID: 30060812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.
    Shaw J; Costa-Pinheiro P; Patterson L; Drews K; Spiegel S; Kester M
    Adv Cancer Res; 2018; 140():327-366. PubMed ID: 30060815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingolipid targets in cancer therapy.
    Modrak DE; Gold DV; Goldenberg DM
    Mol Cancer Ther; 2006 Feb; 5(2):200-8. PubMed ID: 16505092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer treatment strategies targeting sphingolipid metabolism.
    Oskouian B; Saba JD
    Adv Exp Med Biol; 2010; 688():185-205. PubMed ID: 20919655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
    Gatt S; Dagan A
    Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving concepts in cancer therapy through targeting sphingolipid metabolism.
    Truman JP; García-Barros M; Obeid LM; Hannun YA
    Biochim Biophys Acta; 2014 Aug; 1841(8):1174-88. PubMed ID: 24384461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceramide synthesis and metabolism as a target for cancer therapy.
    Reynolds CP; Maurer BJ; Kolesnick RN
    Cancer Lett; 2004 Apr; 206(2):169-80. PubMed ID: 15013522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Drug Transporter P-Glycoprotein and Its Impact on Ceramide Metabolism-An Unconventional Ally in Cancer Treatment.
    Ung J; Kassai M; Tan SF; Loughran TP; Feith DJ; Cabot MC
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.
    Ponnusamy S; Meyers-Needham M; Senkal CE; Saddoughi SA; Sentelle D; Selvam SP; Salas A; Ogretmen B
    Future Oncol; 2010 Oct; 6(10):1603-24. PubMed ID: 21062159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.
    Beckham TH; Elojeimy S; Cheng JC; Turner LS; Hoffman SR; Norris JS; Liu X
    Expert Opin Ther Targets; 2010 May; 14(5):529-39. PubMed ID: 20334489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mechanisms of action of classical chemotherapeutic agents on sphingolipid pathways.
    Hajj C; Becker-Flegler KA; Haimovitz-Friedman A
    Biol Chem; 2015 Jun; 396(6-7):669-79. PubMed ID: 25719313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel agents targeting bioactive sphingolipids for the treatment of cancer.
    Adan-Gokbulut A; Kartal-Yandim M; Iskender G; Baran Y
    Curr Med Chem; 2013; 20(1):108-22. PubMed ID: 23244584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance.
    Giussani P; Tringali C; Riboni L; Viani P; Venerando B
    Int J Mol Sci; 2014 Mar; 15(3):4356-92. PubMed ID: 24625663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingolipids and response to chemotherapy.
    Dimanche-Boitrel MT; Rebillard A
    Handb Exp Pharmacol; 2013; (216):73-91. PubMed ID: 23563652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the ceramide system in cancer.
    Henry B; Möller C; Dimanche-Boitrel MT; Gulbins E; Becker KA
    Cancer Lett; 2013 May; 332(2):286-94. PubMed ID: 21862212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of sphingolipid metabolism in cancer.
    Ryland LK; Fox TE; Liu X; Loughran TP; Kester M
    Cancer Biol Ther; 2011 Jan; 11(2):138-49. PubMed ID: 21209555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of sphingolipid metabolism: from synthesis to breakdown.
    Gault CR; Obeid LM; Hannun YA
    Adv Exp Med Biol; 2010; 688():1-23. PubMed ID: 20919643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingolipid metabolism enzymes as targets for anticancer therapy.
    Kok JW; Sietsma H
    Curr Drug Targets; 2004 May; 5(4):375-82. PubMed ID: 15134220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death.
    Dagan A; Wang C; Fibach E; Gatt S
    Biochim Biophys Acta; 2003 Sep; 1633(3):161-9. PubMed ID: 14499735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.